IPTACOPAN HYDROCHLORIDE | N218276 | NOVARTIS PHARMACEUTICALS CORP
| Code | Date | Status |
|---|---|---|
| I-949 | Aug 7, 2027 | Active |
| I-963 | Mar 20, 2028 | Active |
| NCE | Dec 5, 2028 | Active |
| ODE-456 | Dec 5, 2030 | Active |
| ODE-524 | Mar 20, 2032 | Active |
Novartis received pediatric exclusivity for Fabhalta (iptacopan hydrochloride), adding six months to the regulatory exclusivity period for this complement C3 inhibitor.
New: New record